The 2025 AMA CPT Editorial Panel shows declining code approvals. Discover what this means for MedTech innovators and how to strengthen your coding strategy.
Learn when to pursue a National Coverage Determination (NCD) and what CMS’s renal denervation decision means for MedTech reimbursement and evidence strategy.
FDA approval doesn’t guarantee insurance payment. Learn why payers reject FDA-cleared devices—and how startups can align early with reimbursement strategies.
Discover why payer dossiers are critical for MedTech startups, even in early stages. Learn how they guide evidence development, coding, and reimbursement strategy.